



**Health**

Public Health  
4<sup>th</sup> Floor; 300 Carlton Street Winnipeg MB R3B 3M9  
[vaccines@gov.mb.ca](mailto:vaccines@gov.mb.ca)

November 8, 2022

Dear Health Care Providers:

**COVID-19 Vaccine: Prioritization of Moderna/Spikevax™ Infant Pediatric for second doses and primary series of immunocompromised children aged 6 months to ≤ 4 years**

Manitoba received a limited supply of the Moderna/Spikevax™ infant pediatric COVID-19 vaccine (25 mcg) since its approval in July 2022 and will not be receiving further shipments from our federal partners.

Please be advised that the Moderna/Spikevax™ infant pediatric (25 mcg) vaccine should now be prioritized to complete the primary series for infants and children who have already started with Moderna/Spikevax™ infant pediatric (25 mcg) vaccine or to initiate a primary series for those who are moderately to severely immunocompromised.

Infants aged 6 months to 4 years who are starting their primary series and are immunocompetent should be offered the Pfizer/Comirnaty™ (3 mcg) COVID-19 vaccine.

This transition is to ensure that we have enough supply of the Moderna/Spikevax™ infant pediatric (25 mcg) vaccine for those who need it and is consistent with the National Advisory Committee on Immunizations' strong recommendation to preferentially offer the Moderna/Spikevax™ vaccine for infants and children who are moderately to severely immunocompromised.

Please share this information with all relevant colleagues in your facility/clinic.

Sincerely,

*“Original Signed By:”*

Richard Baydack, PhD  
Director  
Communicable Disease Control

*“Original Signed By:”*

Natalie Casaclang MD, CCFP, FRCPC  
Medical Officer of Health  
Communicable Disease Control